Quality of Life Improvement During Chemotherapy
Launched by CHRISTIAN SCHWEGLER · Jan 4, 2021
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, taking place at the University Hospital Basel, is studying how structured hypnotherapy can improve the quality of life for women undergoing chemotherapy for breast cancer. The trial involves two groups: one group will receive 10 sessions of hypnotherapy along with their usual cancer treatment, while the other group will only receive the standard treatment without any additional therapy. Researchers want to see if the women who have hypnotherapy feel better overall, experience fewer side effects from chemotherapy, and have less anxiety and depression.
To participate in this trial, women must be at least 18 years old, diagnosed with primary breast cancer, and currently receiving chemotherapy. However, those with certain psychological disorders or cognitive issues that might interfere with the study will not be eligible. Participants can expect no risks from the hypnotherapy sessions, and if the study shows positive results, this treatment could be included in future care for breast cancer patients.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Minimum Age 18 years
- • Female
- • Primary breast cancer
- • Receiving neo-adjuvant or adjuvant chemotherapy
- Exclusion Criteria:
- • Verbal or cognitive deficits that are not compatible with outpatient psychotherapy
- • Not consenting patients and vulnerable persons
- • Psychological disorders that prevent patients from participating in the study (e.g. psychotic disorder)
- • acute suicidality
About Christian Schwegler
Christian Schwegler is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, Schwegler's initiatives span various therapeutic areas, emphasizing rigorous study design and adherence to ethical standards. By fostering collaboration among healthcare professionals, researchers, and regulatory bodies, he aims to facilitate the efficient development of safe and effective treatments. Schwegler's expertise in clinical trial management and his proactive approach to stakeholder engagement ensure the successful execution of trials that contribute to the body of medical knowledge and enhance patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, Basel Stadt, Switzerland
Patients applied
Trial Officials
Isabel Ge, Dr.
Study Director
University Hospital, Basel, Switzerland
Christian Schwegler, Dr.
Principal Investigator
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials